Immune Monitoring Core

免疫监测核心

基本信息

批准号：
7484182
负责人：
JOHN D ALTMAN
金额：
$ 31.1万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7484182
关键词：
Acquired Immunodeficiency Syndrome Acute Amino Acids Antibodies Antibody Formation Antigens Arts Binding Biological Assay Blood specimen CD8B1 gene Caspase Cells Clinical Trials Color Complement Consensus Data Detection Development End Point Flow Cytometry Fluorescence HIV HIV Antibodies HIV Envelope Protein gp120 HIV vaccine Human Immune response Immunologic Monitoring Interferons Interleukin-2 Laboratories Macaca mulatta Measures Numbers Peptides Peripheral Blood Mononuclear Cell Process Protocols documentation Reagent Research Sample Size Sampling Serum Staining method Stains T-Lymphocyte T-Lymphocyte Subsets Testing Time United States National Institutes of Health Vaccinated Vaccination Vaccine Antigen Vaccines Validation Vertebral column Viral Virus Work base cytokine design doxorubicin/mitomycin/vinblastine protocol human subject instrument interest neutralizing antibody novel pre-clinical preclinical study programs research study response vector

项目摘要

CORE C DESCRIPTION: Induction of HIV-specific immune responses is both a primary endpoint in the preclinical studies and a secondary endpoint in the clinical trial of novel MVA-based vaccines described in this IPCAVD application. Core C, the Immune Monitoring Core (IMC) of this application will perform state-of-the-art assays of both humoral and cellular immune responses for Projects 1 and 2 which describe preclinical experiments in rhesus macaques designed to determine the best MVA-based vectors to carry forward into a human clinical trial. The IMC will also perform these assays for the human clinical trial described in Core B. The Specific Aims of the IMC are: (1) to evaluate T cell immune responses to the HIV vaccine antigens, using validated Intracellular Cytokine Staining (ICS), ELISpot, and flow cytometry-based proliferation assays; (2) to test serum samples from vaccinated subjects for both HIV-binding and -neutralizing antibodies.

核心 C 描述：HIV 特异性免疫反应的诱导是主要终点本 IPCAVD 申请中描述的基于 MVA 的新型疫苗的临床前研究和临床试验的次要终点。核心 C，该应用程序的免疫监测核心 (IMC) 将为项目 1 和 2 进行最先进的体液和细胞免疫反应测定，这些测定描述了恒河猴的临床前实验，旨在确定最佳的基于 MVA 的方法载体进行人体临床试验。 IMC 还将针对核心 B 中描述的人体临床试验进行这些测定。 IMC 的具体目标是：(1) 使用经过验证的细胞内细胞因子染色 (ICS)、ELISpot 评估 T 细胞对 HIV 疫苗抗原的免疫反应和基于流式细胞术的增殖测定； (2) 检测已接种疫苗受试者的血清样本中的 HIV 结合抗体和中和抗体。